Dermavant is committed to fostering unprecedented change and unparalleled impact in immuno-dermatology.

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant at-a-glance

- A biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA, Raleigh-Durham, NC, and Dallas, TX

About Dermavant

A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development.

The company's medical dermatology pipeline includes commercialized, late-stage, and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Dermavant recently launched its first product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults, one of the largest growing immuno-dermatology markets. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children. Atopic dermatitis affects approximately 26 million people in the United States.

Management team

Todd Zavodnick
Chief Executive Officer

Philip M. Brown, MD, JD
Chief Medical Officer

Chris Chapman
Chief Commercial Officer

David Rubenstein, MD, PhD
Chief Scientific Officer

Michael Swartzburg
Chief Financial Officer

Christopher Van Tuyl, JD
Chief Legal Officer

IMPORTANT SAFETY INFORMATION

Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. **Adverse Events:** The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Medical Information
medinfo@dermavant.com

To learn more,
visit **www.dermavant.com**

Dermavant has VTAMA® cream and candidates in development addressing:

Adult Plaque Psoriasis, Atopic Dermatitis, and Immunological and Inflammatory Diseases

PRODUCT CANDIDATE	POTENTIAL INDICATION	STAGE OF DEVELOPMENT
		Preclinical · Phase 1 · Phase 2 · Phase 3 · FDA Review · Commercial
VTAMA® (DMVT-505) A topical aryl hydrocarbon receptor (AhR) agonist	Adult Plaque Psoriasis	
Tapinarof (DMVT-505) A topical aryl hydrocarbon receptor (AhR) agonist	Atopic Dermatitis	
DMVT-506 Next generation aryl hydrocarbon receptor (AhR) agonist under development for multiple routes of administration	Immunological and Inflammatory Diseases	

dermavant®

1-8-DERMAVANT (1-833-762-8268)

Company locations:

Long Beach, California Office
Dermavant Sciences, Inc.
3780 Kilroy Airport Way, Suite 250
Long Beach, CA 90806

Dallas, Texas Office
Dermavant Sciences, Inc.,
2102 E. State Hwy. 114, Suite 217
Southlake, Texas 76092

Raleigh-Durham, North Carolina Office
Dermavant Sciences, Inc.
3300 Paramount Parkway, Suite 150
Morrisville, NC 27560

Basel, Switzerland Office
Dermavant Sciences GmbH
Viaduktstrasse 8
4051 Basel